Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma

Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Cancer (Impact Factor: 4.89). 07/2005; 104(2):388-94. DOI: 10.1002/cncr.21166
Source: PubMed


Approximately 5-10% of pancreatic carcinoma (PC) patients report a family history of the disease. In some families, mutations of tumor suppressor genes have been elucidated, but for most the causative gene remains unidentified. Counseling the families of PC patients regarding their risk of cancer remains problematic because little information is available.
The authors analyzed family history questionnaires completed by 426 unselected, sequential Mayo Clinic patients with PC. The prevalence of malignancy reported among 3355 of their first-degree relatives was compared with the Surveillance, Epidemiology, and End Results Project (SEER) 9 (2000) registry. Age-adjusted and gender-adjusted standardized incidence ratios (SIRs) were generated.
Greater than 130,000 person-years at risk for cancer among the first-degree relatives were analyzed. The risk of PC was found to be increased among the first-degree relatives of patients with PC (SIR of 1.88; 95% confidence interval [95% CI], 1.27-2.68), as was the risk of liver carcinoma (SIR of 2.70; 95% CI, 1.51-4.46). Lymphoma (SIR of 0.28; 95% CI, 0.12-0.55), bladder carcinoma (SIR of 0.55; 95% CI, 0.31-0.89), breast carcinoma (SIR of 0.73; 95% CI, 0.57-0.92), lung carcinoma (SIR of 0.62; 95% CI, 0.47-0.80), and prostate carcinoma (SIR of 0.71; 95% CI, 0.54-0.92) were found to be underrepresented. When the proband was age < 60 years, the risk of PC to first-degree relatives was found to be increased further (SIR of 2.86; 95% CI, 1.15-5.89). In this subgroup, no other malignancies were found to be significantly increased, although the risks of melanoma (SIR of 1.73; 95% CI, 0.70-3.57), ovarian carcinoma (SIR of 2.20; 95% CI, 0.72-5.12), and colon carcinoma (SIR of 1.37; 95% CI, 0.80-2.19) were suggestive.
There was a nearly twofold increased risk of PC in the first-degree relatives of PC probands. This risk was found to increase nearly threefold when patients were diagnosed before age 60 years. At the current time, in the absence of a pedigree suggestive of known familial cancer syndromes, the current study results do not support targeted screening for other malignancies in the first-degree relatives of patients with sporadic PC.

Download full-text


Available from: Mariza Andrade, Oct 14, 2014
10 Reads
  • Source
    • "These low penetrant genes which by themselves have small relative risks, by virtue of being common in the population may have large population, attributable risks [10]. It has been observed from epidemiological studies that the first-degree relatives of sporadic cancer patients have a 2-3-fold higher risk of developing cancer at the same site and this has also been described for pancreatic cancer but in only retrospective studies [10] [11] [12]. Familial clustering observed in certain sporadic cancers without obvious Mendelian inheritance suggests that there is a genetic component in addition to environmental factors [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To examine interaction between history of cancer in first-degree relatives and tobacco smoking in index patients of pancreatic adenocarcinoma. Methods. We carried out a case-control involving 113 patients with pancreatic adenocarcinoma and 110 controls over a 12-month period at the Freeman Hospital, Newcastle upon Tyne, UK. They were all administered a detailed tobacco exposure questionnaire and a family history questionnaire. We calculated cumulative tobacco exposure and risk for pancreas cancer. Results. Both smokers (OR 3.01 (95% CI: 1.73 to 5.24)) and those with a family history of malignancy (OR 1.98 (95% CI: 1.15–3.38)) were more likely to develop pancreatic cancer. Having more than one first-degree relative with cancer did not significantly further increase the risk of pancreatic cancer. Amongst pancreatic cancer cases, cumulative tobacco exposure was significantly decreased (P = .032) in the group of smokers (current and ex-smokers) who had a family history of malignancy [mean (SD): 30.00 (24.77) pack-years versus 44.69 (28.47) pack-years with no such history]. Conclusions. Individuals with a family history of malignancy are at an increased risk of pancreatic cancer. Furthermore, individuals with a family history of malignancy and who smoke appear to require a lesser degree of tobacco exposure for the development of pancreatic cancer.
    Journal of Oncology 04/2011; 2011(3):215985. DOI:10.1155/2011/215985
  • Source
    • "Familial aggregation of pancreatic tumours E Hiripi et al 1794 British Journal of Cancer (2009) 101(10), 1792 – 1797 & 2009 Cancer Research UK pancreatic cancer risk among spouses of pancreatic cancer patients (Hemminki and Jiang, 2002). In agreement with previous studies, our analysis confirmed an increased risk of pancreatic cancer among individuals with a family history of pancreatic cancer (Hemminki and Li, 2003a; McWilliams et al, 2005). The fact that the risk of pancreatic cancer associated with sibling history was higher might indicate a recessive mode of inheritance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to characterise the familial association of pancreatic cancer with other malignancies. Relative risks (RRs) of pancreatic cancer according to family history of cancer were calculated using the updated Swedish Family-Cancer Database, which includes over 11.5 million individuals. Estimates were based on Poisson regression. RRs of tumours for individuals with a parental history of pancreatic cancer were also estimated. The risk of pancreatic cancer was elevated in individuals with a parental history of cancers of the liver (RR 1.41; 95% CI 1.10-1.81), kidney (RR 1.37; 95% CI 1.06-1.76), lung (RR 1.50; 95% CI 1.27-1.79) and larynx (RR 1.98; 95% CI 1.19-3.28). Associations were also found between parental history of pancreatic cancer and cancers of the small intestine, colon, breast, lung, testis and cervix in offspring. There was an increased risk of pancreatic cancer associated with early-onset breast cancer in siblings. Pancreatic cancer aggregates in families with several types of cancer. Smoking may contribute to the familial aggregation of pancreatic and lung tumours, and the familial clustering of pancreatic and breast cancer could be partially explained by inherited mutations in the BRCA2 gene.
    British Journal of Cancer 10/2009; 101(10):1792-7. DOI:10.1038/sj.bjc.6605363 · 4.84 Impact Factor
  • Source
    • "Pancreatic cancer is more common in men (male:female ratio 1.3:1) and is unusual before the age of 45 years but the incidence rises sharply thereafter, reaching a peak in the mid to late 70s. The majority of cases have no obvious genetic predisposition but 5–10% of patients have a first-degree relative with the disease, suggesting some form of familial aggregation (McWilliams et al. 2005; McFaul et al. 2006). The risk of developing pancreatic cancer is increased in a number of familial cancer syndromes (Vitone et al. 2006); for example, the lifetime risk in Peutz-Jegher syndrome approaches 36% (Giardiello et al. 2000; Latchford et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: More than 90% of patients with pancreatic cancer present either with incurable locally advanced or metastatic disease or relapse following surgery. For these patients systemic therapy offers the only prospect of salvage, but pancreatic cancer is one of the most chemoresistant of tumors; current chemotherapy can only delay progression in a limited proportion of patients and survival rates are poor. There is therefore a pressing need for more effective therapy. Capecitabine is a new oral prodrug of fluorouracil, which has shown activity in pancreatic cancer particularly when used in combination with gemcitabine. To review the emerging evidence for the clinical effectiveness of capecitabine in the management of carcinoma of the pancreas. There is evidence from phase II testing that capecitabine is active in pancreatic cancer. The Swiss Group for Clinical Cancer Research/Central European Cooperative Oncology Group (SAKK/CECOG) phase III trial found that the combination of gemcitabine and capecitabine did not improve overall median survival as compared with gemcitabine alone (8.4 vs 7.3 months, respectively; P=0.314) but subgroup analysis in patients with good performance score [Karnofsky Performance Scores (KPS) ≥90] revealed a significant survival improvement with the combination arm (10.1 months) compared with single-agent gemcitabine (7.5 months; P=0.033). Preliminary data from the GemCap phase III trial indicated significantly improved response rates and survival for the combination of gemcitabine with capecitabine (7.4 months) compared with gemcitabine alone (6 months; P=0.026) but analysis of the mature data with adequate follow-up awaits reporting. The addition of capecitabine to gemcitabine may represent a small step forward in the management of advanced pancreatic cancer but further data are required in order to determine its full impact.
    Core Evidence 11/2007; 2(2):111-9.
Show more